Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed FCF Margin for 6 consecutive years, with 51.7% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 1442.0% to 51.7% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 40.06% through Dec 2025, up 946.0% year-over-year, with the annual reading at 40.06% for FY2025, 946.0% up from the prior year.
  • FCF Margin hit 51.7% in Q4 2025 for Harmony Biosciences Holdings, up from 45.38% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 51.7% in Q4 2025 to a low of 18.33% in Q1 2025.
  • Historically, FCF Margin has averaged 33.99% across 5 years, with a median of 36.51% in 2023.
  • Biggest five-year swings in FCF Margin: surged 15558bps in 2021 and later tumbled -2036bps in 2022.
  • Year by year, FCF Margin stood at 41.15% in 2021, then plummeted by -49bps to 20.79% in 2022, then soared by 119bps to 45.46% in 2023, then dropped by -18bps to 37.29% in 2024, then skyrocketed by 39bps to 51.7% in 2025.
  • Business Quant data shows FCF Margin for HRMY at 51.7% in Q4 2025, 45.38% in Q3 2025, and 39.56% in Q2 2025.